BioRes Ruizhi BLC Implant System Showcased in China, Addressing Rising Demand for High-quality Implants

2025-03-05 Besmile HaiPress

WALNUT,Calif.,March 3,2025 -- BioRes Dentech Inc. showcased its Ruizhi BLC Implant System at Dental South China 2025,a premium product line jointly launched by BioRes Dentech Inc. andBesmile,designed exclusively for China's market. With advanced bone preservation technology and outstanding clinical performance,the system aims to redefine precisionimplantology,addressing the growing demand for reliable,high-quality implants.

Unlocking China's Growing Implant Market Potential

China's dental implant market has grown significantly,yet its implant penetration rate remains low at 59.1 implants per 10,000 people in 2023,far below developed countries,like the U.S. (100-200) and South Korea (500).

This gap highlights immense potential. In 2024,the market generated USD 391.4 million in revenue and is projected to reach USD 618.9 million by 2030,driven by initiatives like bulk procurement,which cut implant costs by 55%.

However,the market still lacks affordable,high-quality implants ensuring long-term stability,raising concerns over failure rates and complications.

BioRes Ruizhi BLC Implant System: A Solution for Lifelong Stability

Partnering withBesmile,BioRes introduces the Ruizhi BLC Implant System,designed for lifelong stability. It minimizes pain and gum disease risks while simplifying procedures for clinicians. Its advanced bone preservation technology promotes alveolar bone retention,ensuring long-term peri-implant tissue stability. The self-tapping design enhances initial stability,safety,and efficiency,addressing critical market needs.

Backed by extensive clinical research,the system boasts a 0% mechanical complication rate over 4 years and a 99.05% success rate over 5 years—surpassing the industry average of 94-96%. These results highlight its reliability and potential to set a new benchmark in dental implant solutions.

About BioRes Dentech Inc.

Based in Walnut,CA,BioRes Dentech Inc. advances dental health through cutting-edge technology and innovation,supporting oral health professionals and enhancing patient outcomes worldwide.

About Chengdu Besmile Biotechnology Co.,Ltd.

Besmile specializes in dental CAD/CAM materials,equipment,and implant systems,delivering cutting-edge digital solutions for dental labs and practices. With in-house R&D and advanced manufacturing,Besmile partnerswith 1,000+ clients in 100+ countries,aiming to lead the global dental industry through innovation and excellence.

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

2The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

6MEXC Claims Dual Wins at BeInCrypto 100 Awards as Best Centralized Exchange and Best Exchange in LATAM

MEXC Claims Dual Wins at BeInCrypto 100 Awards as Best Centralized Exchange and Best Exchange in LATAM

©copyright 2009-2020 Singapore Info Map